Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results
Provided By GlobeNewswire
Last update: Nov 12, 2025
Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A)
On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December 11
Read more at globenewswire.com
